Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists
作者:Michael Berlin、Pauline C. Ting、Wayne D. Vaccaro、Robert Aslanian、Kevin D. McCormick、Joe F. Lee、Margaret M. Albanese、Mwangi W. Mutahi、John J. Piwinski、Neng-Yang Shih、Luli Duguma、Daniel M. Solomon、Wei Zhou、Rosy Sher、Leonard Favreau、Matthew Bryant、Walter A. Korfmacher、Cymbelene Nardo、Robert E. West、John C. Anthes、Shirley M. Williams、Ren-Long Wu、H. Susan She、Maria A. Rivelli、Michel R. Corboz、John A. Hey
DOI:10.1016/j.bmcl.2005.10.087
日期:2006.2
A novel series of histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine template displaying low CYP2D6 and CYP3A4 inhibitory profiles has been identified. Structural features responsible for the reduction of P450 activity, a typical liability of 4-substituted imidazoles, have been established.
基于4-[((1H-咪唑-4-基)甲基]哌啶]模板的新型组胺H3受体拮抗剂已被鉴定,显示出低CYP2D6和CYP3A4抑制特性。已经确定了引起P450活性降低的结构特征,P450活性是4-取代的咪唑的典型特征。